within Pharmacolibrary.Drugs.R_RespiratorySystem.R03B_OtherDrugsForObstructiveAirwayDiseasesInhalants.R03BB54_TiotropiumBromideCombinations;

model TiotropiumBromideCombinations
  extends Pharmacolibrary.Drugs.ATC.R.R03BB54;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03BB54</td></tr><td>route:</td><td>inhalation</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Tiotropium bromide, when used in combination with other bronchodilator agents, is a long-acting muscarinic antagonist (LAMA) used primarily for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. It acts by relaxing airway smooth muscle and improving airflow. The combination products are approved and widely used today for the long-term management of airway obstruction.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for tiotropium bromide in combination products, as no specific published studies are available for pharmacokinetic modeling of the combination. The parameters are based on known single-agent tiotropium data in adult, healthy and COPD populations, assumed to be similar in the fixed-combination inhaled products.</p><h4>References</h4><ol><li><p>Keating, GM (2012). Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease. <i>Drugs</i> 72(2) 273–300. DOI:<a href=\"https://doi.org/10.2165/11208620-000000000-00000\">10.2165/11208620-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22217233/\">https://pubmed.ncbi.nlm.nih.gov/22217233</a></p></li><li><p>Dhillon, S (2016). Tiotropium/Olodaterol: A Review in COPD. <i>Drugs</i> 76(1) 135–146. DOI:<a href=\"https://doi.org/10.1007/s40265-015-0527-2\">10.1007/s40265-015-0527-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26683033/\">https://pubmed.ncbi.nlm.nih.gov/26683033</a></p></li><li><p>ZuWallack, AR, &amp; ZuWallack, RL (2004). Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic-obstructive pulmonary disease. <i>Expert opinion on pharmacotherapy</i> 5(8) 1827–1835. DOI:<a href=\"https://doi.org/10.1517/14656566.5.8.1827\">10.1517/14656566.5.8.1827</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15264997/\">https://pubmed.ncbi.nlm.nih.gov/15264997</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end TiotropiumBromideCombinations;
